Know Cancer

or
forgot password

Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients


Phase 3
18 Years
90 Years
Open (Enrolling)
Both
Seizures (Incl Subtypes), Brain Tumor

Thank you

Trial Information

Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients


Inclusion Criteria:



- Male and females older than 18 years.

- Undergoing supratentorial parenchyma resection surgery.

- Capable of collaborate on probes and explorations included in the study.

- Signature the written informed consent form.

Exclusion Criteria:

- Life expectancy less than 12 months due to the suspected histological type of tumour.

- Hypothalamic-pituitary axis illness.

- Presence of Melanoma previously.

- Glomerular filtration rate less than 60 mL/min.

- Thyroid or parathyroid glands pathology.

- Myasthenia gravis.

- Respiratory depression.

- Pregnancy or breastfeeding.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:

Serum S100B protein

Outcome Time Frame:

2 hours after the end of the surgery

Safety Issue:

No

Principal Investigator

Neus Fabregas, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hospital Clinic of Barcelona

Authority:

Spain: Spanish Agency of Medicines

Study ID:

MAGNA

NCT ID:

NCT01601314

Start Date:

October 2012

Completion Date:

December 2014

Related Keywords:

  • Seizures (Incl Subtypes)
  • Brain Tumor
  • Brain Neoplasms
  • Seizures

Name

Location